News

Proton partners international announces the rutherford cancer centres

22 February 2017: Proton Partners International has announced today it is to name its clinics The Rutherford Cancer Centres.

Read more

The Rutherford Cancer Centres will offer patients a comprehensive range of cancer treatments and, from 2018, will be the first in the UK to offer high energy proton beam therapy.

The oncology centres have been named to reflect the renowned scientist Ernest Rutherford’s contribution in identifying and naming the proton in 1911.

Three centres are currently under development, in Newport, South Wales, Bomarsund, Northumberland and Reading, Berkshire. The Rutherford Cancer Centre, South Wales is nearing completion and will offer chemotherapy, radiotherapy and imaging via the latest planning and treatment technologies. Positron emission tomography–computed tomography (PET-CT) will be available in the second half of this year and proton beam therapy will be available at the centre from early 2018.

Treatment at The Rutherford Cancer Centres will be available to medically-insured private patients, self-paying patients and patients referred by the NHS.

Professor Gordon McVie, chairman of Proton Partners International, said: “We’re delighted to announce the creation of The Rutherford Cancer Centres.

“Proton Partners International is committed to transforming cancer care in the UK. The Rutherford name is synonymous with a major breakthrough in cancer treatment and therefore we felt that this was a fitting identity for our treatment centres.

“With cancer on the rise, there is a growing need for patients to be offered a holistic and sophisticated level of cancer care.  Patients at The Rutherford Cancer Centres will have access to a wide range of cancer services and a treatment plan will be implemented on an individual basis.”

Mike Moran, chief executive officer of Proton Partners International, said: “We are working with the world’s leading technology partners to ensure that our centres are equipped with the latest cancer technology.

“Our centres will have the capacity to treat 500 unique patients a year. We will also network our centres to ensure the data they will provide can play a significant role in cancer research. We are committed to undertaking a genomics programme which will collate, analyse and distribute data through our research facility at the Life Sciences Accelerator centre in Liverpool.”

Notes to Editors

 Contact details

Sophie Watson, Media House International, 0207 710 0020 or Sophie@mediahouse.co.uk

Ramsay Smith, Media House International, 0207 710 0020 or Ramsay@mediahouse.co.uk

About The Rutherford Cancer Centres

The Rutherford Cancer Centres are at the forefront of providing innovative cancer care and creating a better future for cancer patients. With its commitment to excellence, the centres will provide an all-encompassing cancer service, delivering world-class imaging, chemotherapy, radiotherapy and proton beam therapy treatment.

Services will be available to patients under medical insurance self-pay patients and patients referred by the NHS.

About Proton Partners International Ltd

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors committed to almost £100m equity finance in the company.

Professor Gordon McVie, Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), is non-executive chairman and Professor Karol Sikora is chief medical adviser to the company.

The Welsh Government’s Life Sciences Investment Fund is a key investor in Proton Partners International.

For more information on Proton Partners, please visit: http://proton-int.com/

Follow us on twitter @ProtonPartners

Ramsay Smith

Executive Director | Media House International Ltd

t: 0207 710 0020 |​ m:07788 414 856

t: 0141 220 6040 | f: 0141 220 6044

Apitope Announces Positive ATX-MS-1467 Phase IIa Data in Relapsing Multiple Sclerosis

Hasselt, Belgium and Chepstow, UK: 21 February 2017 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis.

Read more
 

The Phase IIa, open-label, one arm study evaluated the effects of ATX-MS-1467 in 19 patients with relapsing multiple sclerosis. The investigational product was administered intradermally (ID) every 2 weeks for 20 weeks. Following a dose titration of 50 and 200 μg in the initial 4 weeks of treatment a dose of 800μg was administered fortnightly for a further of 16 weeks.

There were statistically significant reductions in total and new T1 Gadolinium enhancing lesions measured using MRI during treatment as well as a significant reduction in the volume of T1 Gadolinium enhancing lesions. The data also showed a strong trend towards improvement in the Multiple Sclerosis Functional Composite (MSFC) score that is used clinically as an indicator of improvement in disability. There were no treatment related serious adverse events and the adverse event profile was mild.

Dr Keith Martin, Chief Executive Officer of Apitope, commented: “We are delighted with these positive results that confirm both clinical findings in our Phase Ib trial as well as preclinical results showing significant decreases in MRI detected lesions and disability in a standard multiple sclerosis model. We will continue to progress the development of ATX-MS-1467 as a treatment for multiple sclerosis and are currently preparing for a Phase IIb placebo controlled study to demonstrate clinical efficacy.”

Dr Jeremy Chataway, Consultant Neurologist, National Hospital for Neurology and Neurosurgery, London, commenting on the results said: “Having been the Chief Investigator on the previous Phase Ib study, it is pleasing to see these promising confirmatory Phase IIa results where ATX-MS-1467 has shown both an encouraging efficacy and an excellent safety and tolerability profile. While these patients were only treated for 20 weeks, results in a Phase IIb study with a longer treatment period will be interesting.”

The compound had previously completed a Phase I clinical study in six patients with secondary progressive multiple sclerosis (SPMS) and a second Phase I study in 43 relapsing multiple sclerosis patients, assessing safety and biological parameters. The latest results support the further development of ATX-MS-1467 in multiple sclerosis.

For further information:

Apitope

Dr Keith Martin, CEO

Tel: +44 (0)1291 63 55 11

keith.martin@apitope.com

For media enquiries:

Hume Brophy

Conor Griffin, Alexia Faure, Alexander Protsenko

Tel: +44 (0)20 7862 6381

apitope@humebrophy.com

 About Apitope

Apitope is a European biotech company focused on the discovery and development of disease modifying therapies for abnormal immune responses including autoimmune diseases such as, multiple sclerosis, Graves’ disease, and uveitis; and Factor VIII intolerance

Apitope has a patented discovery platform which enables selection of disease-modifying peptide therapies for the target of interest; and has already generated a pipeline of seven programmes in clinical and preclinical development, of which the lead programme in multiple sclerosis is in Phase II. The discovery engine selects Apitopes™ – Antigen Processing Independent epiTOPES. Apitopes are soluble, synthetic peptides from the human sequence which can selectively suppress abnormal immune responses and reinstate the normal immune balance. Stakeholders in the company include Wales Life Sciences Fund, Vesalius Biocapital, LRM, the Wellcome Trust and the US MS charity, Fast Forward.

About ATX-MS-1467

Apitope’s lead product candidate is ATX-MS-1467, a potentially disease-modifying therapy for the treatment of multiple sclerosis, is a novel peptide-based therapeutic identified using Apitope’s proprietary technology platform.

It consists of four short peptides that are derived from myelin basic protein, a key autoantigen in multiple sclerosis. It is designed to induce immunological tolerance of the body’s T cells to key autoantigens thought to be involved in the pathogenesis of multiple sclerosis.

For more information on the Company, please visit: www.apitope.com 

Alexander Protsenko

Consultant

Hume Brophy | 55 King William Street | London EC4R 9AD | UK

DD +44 (0)20 7862 6397 | T +44 (0)20 7862 6481 | M +44 (0)73 9376 5184

alex.protsenko@humebrophy.com